… to sorafenib-induced HCC cell-growth inhibition. Sorafenib inhibited cell growth in both cell
… and 2011 transcripts in HepG2 and Huh7 cells, respectively. Genes functionally involved in …

… treated with this drug suggests that a possible way to enhance the therapeutic power of
sorafenib could be its combination with glycolytic inhibitors, such as oxamate, which blocks …

… Sorafenib (BAY 43-9006, Nexavar) is a multikinase inhibitor with activity against Raf kinase
and several receptor tyrosine kinases, including vascular endothelial growth factor receptor …

… The novel anticancer agent sorafenib is a multi-kinase inhibitor of more … Sorafenib has been
shown to inhibit tumor cell proliferation by blocking the Ras/Raf/MAPK pathway and to inhibit …

… Sorafenib induces apoptosis in multiple cancer cell lines by downregulating and inhibiting
the translation of Mcl-1, a Bcl-2 family member (Fig. 1a).17 The pro-survivor factor Mcl-1 …

… Sorafenib may inhibit tumor growth by combining two anticancer activities: inhibition of
tumor cell proliferation and survival (through C‐RAF and B‐RAF) and tumor angiogenesis (…

… Being a multi-target kinase inhibitor, sorafenib can block tumor cell proliferation by … have
also found that sorafenib is effective in various tumor cells, such as breast cancer MDA-MB-231 (…

… show that sorafenib sensitizes resistant HCC cells to TRAIL-induced apoptosis through
SHP-1–dependent STAT3 inhibition. The molecular mechanism by which sorafenib overcomes …

… inhibitor of autophagy by downregulating Beclin-1. In this study, we characterized the role of
miR-30a in sorafenib-induced activity in renal cell carcinoma (RCC) cells. … in RCC cell lines. …

… To establish the synergistic antiproliferative effect of the combination of sorafenib and
EGFR inhibitors, we performed cell counting experiments on the two most resistant HCC …